Camostat is a serine protease indicated in Japan to treat chronic pancreatitis. Camostat mesylate, or FOY-305, is a synthetic serine protease inhibitor.
- Mechanism
- Curator reviewed · 4 references
In rats, oral camostat mesylate may increase pancreatic secretions and hypertrophy by increasing cholecystokinin release. Administration in rats has also lead to lower levels of IL-1beta, IL-6, TNF-alpha, TGF-beta, and PSC. Similar activity is seem after administration in humans, leading to reduced pain and inflammation as well as improve the function of the pancrease in chronic pancreatitis.
In the case of SARS-CoV-2, camostat mesylate inhibits the action of the serine protease TMPRSS2, preventing the priming of the viral spike protein for attachment to ACE2, and entry into the cell.
- Primary indication
- Camostat mesylate is indicated in Japan to treat chronic pancreatitis and drug induced lung injury.Curator reviewed
- Formula / weight
- C20H22N4O5 · 398.4125 g/mol (avg)
Resolves to
XASIMHXSUQUHLV-UHFFFAOYSA-NSMILESCN(C)C(=O)COC(=O)CC1=CC=C(OC(=O)C2=CC=C(NC(N)=N)C=C2)C=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Camostat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account